title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 4, Slide 2

description:
Library name: Sample 301
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 4, Slide 2

status: Public on Dec 21 2025

type: SRA

city: Boston

first: Jonathan

middle: Andrew

last: Nowak

state: MA

address: 75 Francis St.

department: Pathology

country: USA

institute: Brigham and Women's Hospital

description:
Library name: Sample 302
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

library_source: transcriptomic

data_processing:
GeoMx DSP data were pre-processed using the GeoMxTools package (version 3.8.0) in R. DCC files containing raw count data from NGS, the PKC file pertaining to the GeoMx Human WTA, and a custom-made annotation file derived from the FASTQ lab worksheet files were condensed into an object of the GeoMxSetObject class. The GeoMxSetObject contained a total of 716 areas of illumination (AOIs) prior to quality control. AOIs were excluded from further analysis based on read metrics, sequencing saturation, and nuclei count. Probes were excluded from further analysis based on count distribution across AOIs and an outlier test and were then condensed into a gene-level count matrix. Next, all AOIs with at least 1% of genes detected and all genes detected in at least 1% of AOIs were retained in the dataset. After these quality control steps, a total of 676 AOIs remained in the dataset. Batch correction was then performed using the ComBat-Seq algorithm as implemented in the sva R package (3.52.0). Finally, count data were normalized to the third quantile and log2-transformed for downstream analysis.
AOIs were excluded from further analysis based on read metrics, sequencing saturation, and nuclei count.
Probes were excluded from further analysis based on count distribution across AOIs and an outlier test and were then condensed into a gene-level count matrix.
Next, all AOIs with at least 1% of genes detected and all genes detected in at least 1% of AOIs were retained in the dataset.
Batch correction was then performed using the ComBat-Seq algorithm as implemented in the sva R package (3.52.0).
Finally, count data were normalized to the third quantile and log2-transformed for downstream analysis.
Assembly: hg38
Supplementary files format and content: DCC files: Contains target probe counts linked to one area of illumination per file with quality control metadata.
Supplementary files format and content: PKC file: Contains information regarding the Geomx Whole Transcriptome Atlas gene panel.
Supplementary files format and content: annotation_file.xlsx: Derived from lab worksheets produced from each individual run and contains relevant metadata required for analysis as published, including de-identified patient characteristics, anatomic site of origin, and time of biopsy in relation to treatment.
Supplementary files format and content: GeoMxSetObject_postQC.RDS: Third-quartile normalized and batch-corrected data object used in all downstream analysis.
Library strategy: Spatial Transcriptomics

molecule: total RNA

organism: Homo sapiens

source_name: metastatic pancreatic adenocarcinoma

extract_protocol:
Two tumor biopsies were performed on most patients. One biopsy was performed during screening and one was performed after 4-6 weeks of treatment from the same metastatic site to acquire cores for formalin-fixed, paraffin-embedded (FFPE) blocks, frozen OCT blocks, and fresh tissue studies. Slides from FFPE tissue were hematoxylin and eosin (H&E)-stained, followed by review by a pathologist. If no viable tumor was identified in FFPE cores, OCT cores were converted to FFPE blocks if available.
The GeoMx DSP libraries were prepared according to the manufacturer's instructions for the GeoMx Human Whole Transcriptome Atlas (WTA) assay.

treatment_protocol: Each treatment cycle consisted of 28 days. All patients whose samples are represented in this study received albumin-bound paclitaxel followed by gemcitabine (GA). Albumin-bound paclitaxel was administered as a 30-minute infusion at a dose of 125 mg/m2 (maximum infusion time not to exceed 40 minutes) followed by 1000 mg/m2 gemcitabine as a 30-minute infusion for three consecutive weeks followed by a week of rest (treatment on days 1, 8, and 15, during a 28-day cycle). Patients assigned to the GA plus oral placebo arm received an oral placebo taken once daily that could not be physically distinguished from the oral paricalcitol pill. Patients assigned to the GA plus intravenous (IV) paricalcitol arm were initially scheduled to receive 25 mcg of IV paricalcitol three times weekly. However, due to clinical care restrictions imposed during the COVID pandemic, the dose was reduced to 75 mcg of IV paricalcitol weekly. Only one patient received thrice weekly dosing prior to the dosing change. Patients assigned to the GA plus PO paricalcitol arm received 16 mcg of oral paricalcitol daily, which was thought to be analogous to a cumulative weekly dose as 75 mcg of IV paricalcitol based upon the bioavailability of PO paricalcitol.

tag: tissue

value: metastatic pancreatic adenocarcinoma

tag: biopsy site

value: lung

tag: segment

tag: region of_interest_number

tag: patient id

tag: treatment

tag: biopsy timepoint

value: pre-treatment

tag: Sex

value: F

tag: race

value: White

tag: ethnicity

value: Non-Hispanic

tag: age

tag: batch


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 6, Slide 2

description:
Library name: Sample 309
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 322
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: omentum


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 3, Slide 2

description:
Library name: Sample 300
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 5, Slide 2

description:
Library name: Sample 304
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: Center


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 3, Slide 2

description:
Library name: Sample 298
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 2, Slide 2

description:
Library name: Sample 297
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID78, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 320
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1, Slide 2

description:
Library name: Sample 294
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2, Slide 2

description:
Library name: Sample 295
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1, Slide 2

description:
Library name: Sample 293
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1, Slide 2

description:
Library name: Sample 292
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 7

description:
Library name: Sample 289
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: liver

value: M


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 288
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 7

description:
Library name: Sample 291
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2, Slide 2

description:
Library name: Sample 296
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 7

description:
Library name: Sample 290
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 285
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 281
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 3, Slide 2

description:
Library name: Sample 299
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 287
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 4

description:
Library name: Sample 282
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 278
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 280
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 286
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 279
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 283
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 275
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 276
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 277
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 273
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 274
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 271
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Full ROI, 6

description:
Library name: Sample 269
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: peritoneum

value: Full ROI

value: on-treatment


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 272
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Full ROI, 7

description:
Library name: Sample 270
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 4

description:
Library name: Sample 267
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 4

description:
Library name: Sample 266
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Full ROI, 5

description:
Library name: Sample 268
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 3

description:
Library name: Sample 265
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 264
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID80, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 284
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 1

description:
Library name: Sample 261
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring2, 2

description:
Library name: Sample 263
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 260
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 258
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 255
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 256
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 252
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 4

description:
Library name: Sample 253
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 250
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 249
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 248
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 247
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 245
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 244
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 242
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 6

description:
Library name: Sample 241
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: Gemcitabine/Nab-Paclitaxel plus Placebo


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 246
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 6

description:
Library name: Sample 240
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 6

description:
Library name: Sample 239
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 243
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 4

description:
Library name: Sample 236
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 4

description:
Library name: Sample 235
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 262
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 3

description:
Library name: Sample 234
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 3

description:
Library name: Sample 233
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 259
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 5

description:
Library name: Sample 237
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 2

description:
Library name: Sample 231
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 257
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 254
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 2

description:
Library name: Sample 230
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID92, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 251
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 1

description:
Library name: Sample 228
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 1

description:
Library name: Sample 229
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID69, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 226
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID69, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 225
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID69, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 227
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID69, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 224
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Full ROI, 2

description:
Library name: Sample 222
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID70, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, on-treatment, Full ROI, 1

description:
Library name: Sample 221
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID69, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 223
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID88, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Full ROI, 3

description:
Library name: Sample 219
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 5

description:
Library name: Sample 238
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID88, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Full ROI, 2

description:
Library name: Sample 218
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID88, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Full ROI, 4

description:
Library name: Sample 220
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID88, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 1

description:
Library name: Sample 216
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: No Template Control 4

description:
Library name: Sample 214
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID73, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, Center, 3

description:
Library name: Sample 232
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID89, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 1

description:
Library name: Sample 211
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID89, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 1

description:
Library name: Sample 210
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 7

description:
Library name: Sample 209
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 5

description:
Library name: Sample 206
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID89, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring1, 2

description:
Library name: Sample 212
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 6

description:
Library name: Sample 207
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID88, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 1

description:
Library name: Sample 217
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 4

description:
Library name: Sample 204
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 5

description:
Library name: Sample 205
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 6

description:
Library name: Sample 208
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 202
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 201
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 1

description:
Library name: Sample 198
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 199
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2, Slide 1

description:
Library name: Sample 197
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 4

description:
Library name: Sample 203
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2, Slide 1

description:
Library name: Sample 196
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 191
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.

value: Other


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1, Slide 1

description:
Library name: Sample 193
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1, Slide 1

description:
Library name: Sample 194
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: No Template Control 3

description:
Library name: Sample 192
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID89, Gemcitabine/Nab-Paclitaxel plus Placebo, on-treatment, ring2, 2

description:
Library name: Sample 213
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID88, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 1

description:
Library name: Sample 215
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID86, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1, Slide 1

description:
Library name: Sample 195
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 190
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 186
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 185
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 187
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 183
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 4

description:
Library name: Sample 184
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 182
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 179
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 181
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 1

description:
Library name: Sample 200
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 180
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 178
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 177
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 175
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID96, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 176
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 7

description:
Library name: Sample 170
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 7

description:
Library name: Sample 171
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 8

description:
Library name: Sample 174
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 7

description:
Library name: Sample 169
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 189
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 8

description:
Library name: Sample 172
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 168
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 167
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 163
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 4

description:
Library name: Sample 162
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 188
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 164
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 166
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 159
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 161
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 156
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 160
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 3

description:
Library name: Sample 158
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 3

description:
Library name: Sample 157
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 151
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 154
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 152
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 153
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID74, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 150
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 8

description:
Library name: Sample 173
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 8

description:
Library name: Sample 142
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID74, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 149
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID74, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 148
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID74, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 147
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 6

description:
Library name: Sample 138
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID74, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 146
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 165
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 8

description:
Library name: Sample 144
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 5

description:
Library name: Sample 134
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID68, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 155
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 4

description:
Library name: Sample 131
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 7

description:
Library name: Sample 141
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 3

description:
Library name: Sample 129
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 3

description:
Library name: Sample 128
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 7

description:
Library name: Sample 140
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 2

description:
Library name: Sample 124
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 6

description:
Library name: Sample 136
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 6

description:
Library name: Sample 137
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 4

description:
Library name: Sample 132
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 5

description:
Library name: Sample 133
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 1

description:
Library name: Sample 123
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 4

description:
Library name: Sample 130
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 5

description:
Library name: Sample 135
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 3

description:
Library name: Sample 127
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 8

description:
Library name: Sample 120
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 2

description:
Library name: Sample 125
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 8

description:
Library name: Sample 119
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID74, Gemcitabine/Nab-Paclitaxel plus Oral Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 145
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 1

description:
Library name: Sample 122
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring1, 8

description:
Library name: Sample 143
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 6

description:
Library name: Sample 112
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 8

description:
Library name: Sample 118
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 6

description:
Library name: Sample 114
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 7

description:
Library name: Sample 116
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 5

description:
Library name: Sample 111
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 7

description:
Library name: Sample 117
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 6

description:
Library name: Sample 113
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 7

description:
Library name: Sample 139
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, Center, 1

description:
Library name: Sample 121
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 5

description:
Library name: Sample 110
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 7

description:
Library name: Sample 115
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID84, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, on-treatment, ring2, 2

description:
Library name: Sample 126
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 5

description:
Library name: Sample 109
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 4

description:
Library name: Sample 107
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 4

description:
Library name: Sample 106
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 3

description:
Library name: Sample 105
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 2

description:
Library name: Sample 102
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 2

description:
Library name: Sample 100
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring2, 1

description:
Library name: Sample 99
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 2

description:
Library name: Sample 101
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, ring1, 1

description:
Library name: Sample 98
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID82, Gemcitabine/Nab-Paclitaxel plus IV Paricalcitol, pre-treatment, Center, 1

description:
Library name: Sample 97
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, Center, 6, Slide 1

description:
Library name: Sample 94
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 6, Slide 1

description:
Library name: Sample 95
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: No Template Control 2

description:
Library name: Sample 96
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring2, 5, Slide 1

description:
Library name: Sample 93
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.


title: ID87, Gemcitabine/Nab-Paclitaxel plus Placebo, pre-treatment, ring1, 5, Slide 1

description:
Library name: Sample 92
A total of 716 areas of illumination were profiled and sequenced, represented by one .DCC file for each area. A total of 8 negative control probes were used, corresponding to each 96-well plate. After quality control and normalization, 676 areas of illumination were represented in the dataset for downstream analysis.